Modulation of bone morphogenetic protein antagonists to stimulate clinical osteogenesis |
| |
Authors: | Jaimo Ahn David JJ de Gorter David L Helfet |
| |
Institution: | a Hospital for Special Surgery & Weill Medical College of Cornell University, New York, NY, USA b Department of Molecular Cell Biology, Leiden University Medical Centre, Leiden, The Netherlands c Department of Orthopaedic Surgery, Academic Medical Center, Amsterdam, The Netherlands |
| |
Abstract: | Bone morphogenetic proteins (BMPs) are important for the development and functioning of a wide variety of tissues and organ systems. Their ability to induce bone formation has been harnessed for clinical application. Specifically, local application of BMPs into fractures and fusions has shown some efficacy in inducing bone formation. However, clinical success has not been as robust as might be expected from the results obtained using animal models. This difference may be due to a number of mechanisms regulating BMP activity in vivo. One class of major regulators is the extracellular antagonist (e.g. Noggin, Gremlin, DAN), the dysfunction of which has been shown to result in ectopic bone formation in animal models and human disease. We hypothesize that local application of BMPs at high concentrations induces increased production of BMP antagonists, thereby limiting BMP activity and clinical efficacy. Therapies blocking the function of BMP antagonists should therefore result in enhanced BMP activity and increased bone formation. Furthermore, titrated systemic regulation of BMP antagonist may potentially reverse osteoporosis. Our collective experience with the clinical use of BMP illustrates the importance of understanding mechanisms of endogenous antagonism and regulation in the exogenous application of a protein as a therapeutic. |
| |
Keywords: | Bone morphogenetic protein BMP antagonists Fracture healing Osteoporosis |
本文献已被 ScienceDirect 等数据库收录! |
|